Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
WEX Q3 2026 adjusted net income per diluted share rises 34% year over year to $6.13

WEX Q3 2026 adjusted net income per diluted share rises 34% year over year to $6.13

BitgetBitget2026/10/29 13:43
  • WEX's third-quarter 2026 adjusted net income per diluted share jumped 34% year over year to $6.13.
  • Revenue rose 13% year over year to $780.1 million, exceeding guidance.
  • Quarterly adjusted free cash flow reached $234.3 million, with 85% returned to shareholders through share repurchases.
  • The Mobility business renewed its largest direct OTR customer by gallons processed.
  • Full-year 2026 guidance targets adjusted net income per diluted share of $21.28-$21.48.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. WEX Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss